ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 on Nivo + Cabo vs. Sunitinib for Advanced RCC: Final OS Analysis and Organ-Specific Target Lesion Assessments w/ 2-Year Follow-Up in CheckMate 9ER

259 views
March 2, 2022
Comments 0
Login to view comments. Click here to Login